{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-036843","form_type":"8-K","ticker":"VNDA","cik":"0001347178","company_name":"Vanda Pharmaceuticals Inc.","filed_at":"2025-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.790629+00:00","generated_at":"2026-05-17T22:13:37.016033+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vanda Q2 net loss widens to $27.2M; Fanapt sales up 27% to $29.3M","bullets":["Fanapt net product sales $29.3M (+27% YoY); HETLIOZ $16.2M (-13%), PONVORY $7.1M (-18%).","Net loss $27.2M (diluted EPS -$0.46) vs. net loss $4.5M (-$0.08) in Q2 2024.","Cash $325.6M, down $15.4M from Q1 2025; full-year revenue guidance reaffirmed $210-250M.","Regulatory milestones: Bysanti NDA PDUFA Feb 21, 2026; Tradipitant NDA PDUFA Dec 30, 2025; Imsidolimab BLA submission expected 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-036843","json":"https://secwatch.observer/filing/0001628280-25-036843.json","markdown":"https://secwatch.observer/filing/0001628280-25-036843.md","text":"https://secwatch.observer/filing/0001628280-25-036843.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1347178/000162828025036843/0001628280-25-036843-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1347178/000162828025036843/vnda-20250731.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T22:13:37.016033+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}